Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus

Neuroscience

Volumn 89, Issue 1, 1999, Pages 167-173

  Mazarati, A ^a,b   Liu, H ^a,b   Wasterlain, C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

opioids; opioids; Hippocampus; Self sustaining status epilepticus

Indexed keywords

BINALTORPHIMINE; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DYNORPHIN[1-13]; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR AGONIST; LEUCINE ENKEPHALIN[2 DEXTRO SERINE 6 THREONINE]; MU OPIATE RECEPTOR AGONIST; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTRINDOLE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; EPILEPTIC STATE; IMMUNOCYTOCHEMISTRY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PERFORANT NERVE TRACT; PHARMACOLOGY; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; DYNORPHINS; ELECTRIC STIMULATION; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, LEUCINE; ENKEPHALINS; IMMUNOHISTOCHEMISTRY; MALE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NEURONS; OPIOID PEPTIDES; PEPTIDE FRAGMENTS; PERFORANT PATHWAY; RATS; RATS, WISTAR; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; STATUS EPILEPTICUS;

EID: 0033105065     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00320-0     Document Type: Article

References (41)

1. Asai M., Matamoros-Trejo G., Talavera E., Cano-Martinez A. and Avila M. E. (1995) Opioid peptides content in the rat brain during the ictal phase and after pentylenetetrazol-kindled rats. Comp. Biochem. Physiol. 112, 241-245.
2. Bausch S. B. and Chavkin C. (1997) Changes in hippocampal circuitry after pilocarpine-induced seizures as revealed by opioid receptor distribution and activation. J. Neurosci. 17, 477-492.
3. Bohme G. A., Stutzmann J. M., Roques B. P. and Blanchard J. C. (1987) Effects of selective mu- and delta-opioid peptides on kindled amygdaloid seizures in rats. Neurosci. Lett. 74, 227-231.
4. Bonhaus D. W., Rigsbee L. C. and McNamara J. O. (1987) Intranigral dynorphin-1-13 suppresses kindled seizures by a naloxone-insensitive mechanism. Brain Res. 405, 358-363.
5. Camacho Ochoa M., Jackson T. A., Aaron C. S., Lahti R. A., Strain G. M. and Von Voigtlander P. F. (1992) Antagonism of kainic acid lesions in the mouse hippocampus by U-54494A and U-50488H. Life Sci. 51, 1135-1143.
6. Cheng J. G. and Xie X. K. (1990) A study on opioid peptides in CSF of patients with epilepsy. Epilepsy Res. 6, 141-145.
7. De Sarro G. B., Marra R., Spagnolo C. and Nistico G. (1992) Delta opioid receptors mediate seizures produced by intrahippocampal injection of ala-deltorphin in rats. Funct. Neurol. 7, 235-238.
8. Drake C. T., Terman G. W., Simmons M. L., Milner T. A., Kunkel D. D., Schwartzkroin P. A. and Chavkin C. (1994) Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J. Neurosci. 14, 3736-3750.
9. Gall C. (1988) Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J. Neurosci. 8, 1852-1862.
10. Garant D. S. and Gale K. (1985) Infusion of opiates into substantia nigra protects against maximal electroshock seizures in rats. J. Pharmac. Exp. Ther. 234, 45-48.
11. Harrison M. B., Shumate M. D. and Lothman E. W. (1995) Opioid peptide expression in models of chronic temporal lobe epilepsy. Neuroscience 65, 785-795.
12. Hong J. S., Grimes L., Kanamatsu T. and McGinty J. F. (1987) Kainic acid as a tool to study the regulation and function of opioid peptides in the hippocampus. Toxicology 46, 141-157.
13. Houser C. R., Miyashiro J. E., Swartz B. E., Walsh G. O., Rich J. R. and Delgado-Escueta A. V. (1990) Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J. Neurosci. 10, 267-282.
14. Hsu S. M. and Raine L. (1981) Protein A, avidin and biotin in immunocytochemistry. J. Histochem. Cytochem. 29, 1349-1353.
15. Iadarola M. J., Shin C., McNamara J. O. and Yang H. Y. (1986) Changes in dynorphin, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling. Brain Res. 365, 185-191.
16. Ikonomidou-Turski C., Cavalheiro E. A., Turski W. A., Bortolotto Z. A. and Turski L. (1987) Convulsant action of morphine, [D-Ala2, D-Leu5]-enkephalin and naloxone in the rat amygdala: Electroencephalographic, morphological and behavioural sequelae. Neuroscience 20, 671-686.
17. Jackson H. C. and Nutt D. J. (1991) Differential effects of selective mu-, kappa- And delta-opioid antagonists on electroshock seizure threshold in mice. Psychopharmacology, Berlin 103, 380-383.
18. Kanamatsu T., Obie J., Grimes L., McGinty J. F., Yoshikawa K., Sabol S. and Hong J. S. (1986) Kainic acid alters the metabolism of Met5-enkephalin and the level of dynorphin A in the rat hippocampus. J. Neurosci. 6, 3094- 3102.
19. Lason W., Simpson J. N. and McGinty J. F. (1989) The interaction between kappa-opioid agonist, U-50488H, and kainic acid: Behavioral and histological assessments. Brain Res. 482, 333-339.
20. Lee P. H., Zhao D., Xie C. W., McGinty J. F., Mitchell C. L. and Hong J. S. (1989) Changes of proenkephalin and prodynorphin mRNAs and related peptides in rat brain during the development of deep prepyriform cortex kindling. Molec. Brain Res. 6, 263-273.
21. Llewellyn-Smith I. L. and Minson J. B. (1992) Complete penetration of antibodies into vibratome sections after glutaraldehyde fixation and ethanol treatment: Light and electron microscopy for neuropeptides. J. Histochem. Cytochem. 40, 1741-1749.
22. Mazarati A. M., Shirasaka Y. and Wasterlain C. G. (1995) Self-sustaining status epilepticus resulting from brief perforant path stimulation in free moving rats. Soc. Neurosci. Abstr. 21, 1960.
23. Mazarati A. M. and Wasterlain C. G. (1997) Loss of hippocampal inhibition and enhanced LTP after self-sustaining status epilepticus. Epilepsia 38 Suppl. 3, 178.
24. Moneta M. E. and Hollt V. (1990) Perforant path kindling induces differential alterations in the mRNA levels coding for prodynorphin and proenkephalin in the rat hippocampus. Neurosci. Lett. 110, 273-278.
25. Nakata Y., Chang K. J., Mitchell C. L. and Hong J. S. (1985) Repeated electroconvulsive shock downregulates the opioid receptors in rat brain. Brain Res. 346, 160-163.
26. Pinsky C., Bose R. and Frederickson R. C. (1986) Mu- and delta-opioid modulation of electrically-induced epileptic seizures in mice. NIDA Res. Monogr. 75, 543-546.
27. Przewlocki R., Kaminska B., Lukasiuk K., Nowicka D. Z., Przewlocka B., Kaczmarek L. and Lason W. (1995) Seizure related changes in the regulation of opioid genes and transcription factors in the dentate gyrus of rat hippocampus. Neuroscience 68, 73-81.
28. Puglisi-Allegra S., Cabib S. and Oliverio A. (1985) Pharmacological evidence for a protective role of the endogenous opioid system on electroshock-induced seizures in the mouse. Neurosci. Lett. 62, 241-247.
29. Racine R. J. (1972) Modification of seizure activity by electrical stimulation. Electroenceph. Clin. Neurophysiol. 32, 281-294.
30. Rocha L. L., Evans C. J. and Maidment N. T. (1997) Amygdala kindling modifies extracellular opioid peptide content in rat hippocampus measured by microdialysis. J. Neurochem. 68, 616-624.
31. Schwark W. S., Frey H. H. and Czuczwar S. J. (1986) Effect of opiates on the parameters of seizures in rats with full amygdaloid-kindled convulsions. Neuropharmacology 25, 839-844.
32. Simmons M. L. and Chavkin C. (1996) Endogenous opioid regulation of hippocampal function. Int. Rev. Neurobiol. 39, 145-196.
33. Talavera E., Omana-Zapata I., Asai M. and Condes-Lara M. (1989) Regional brain IR-Met-, IR-Leu-enkephalin concentrations during progress and full electrical amygdaloid kindling. Brain Res. 485, 141-148.
34. Tortella F. C., Echevarria E., Lipkowski A. W., Takemori A. E., Portoghese P. S. and Holaday J. W. (1989) Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model. Life Sci. 44, 661-665.
35. Tortella F. C., Echevarria E., Robles L., Mosberg H. I. and Holaday J. W. (1988) Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats. Peptides 9, 1177-1181.
36. Tortella F. C. and Long J. B. (1988) Characterization of opioid peptide-like anticonvulsant activity in rat cerebrospinal fluid. Brain Rex. 456, 139-146.
37. Tortella F. C., Robles L., Echevarria E., Hunter J. C. and Hughes J. (1990) PD117302, a selective non-peptide opioid kappa agonist, protects against NMDA and maximal electroshock convulsions in rats. Life Sci. 46, PL1-PL7.
38. Tortella F. C., Robles L. and Holaday J. W. (1985) The anticonvulsant effects of DADLE are primarily mediated by activation of delta opioid receptors: Interactions between delta and mu receptor antagonists. Life Sci. 37, 497-503.
39. Van der Zee C., Rashid K., Le K., Moore K., Stanisz J., Diamond J., Racine R. J. and Fahnestock M. (1995) Intraventricular administration of antibodies to nerve growth factor retards kindling and blocks mossy fiber sprouting in adult rats. J. Neurosci. 15, 5316-5323.
40. Wanscher B., Kragh J., Barry D. I., Bolwig T. and Zimmer J. (1990) Increased somatostatin and enkephalin-like immunoreactivity in the rat hippocampus following hippocampal kindling. Neurosci. Lett. 118, 33-36.
41. Weisskopf M. G., Zalutsky R. A. and Nicoll R. A. (1993) The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibers synapses and modulates long-term potentiation. Nature 362, 451-454.